A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss

Lucky, Anne W.; Piacquadio, Daniel; Ditre, Chérie M.; Dunlap, Frank E.; Kantor, Irwin; Pandya, Amit G.; Savin, Ronald C.; Tharp, Michael D.

doi:10.1016/j.jaad.2003.06.014

Cited by 241 publications

(180 citation statements)

References 15 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…4,23) After 48 weeks of male pattern hair loss treatment, the parameter known as non-vellus hair count (mean change from baseline) in the 5% minoxidil, 2% minoxidil, and placebo groups measured 18.6, 12.7, and 3.9 strands/cm 2 , respectively. 4) The change from baseline in the non-vellus hair count was significantly superior with 5% topical minoxidil compared to The chi-square test was used to evaluate statistically significant between-group differences in the questionnaire analysis.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Rice Bran Supercritical CO<sub>2</sub> Extract for Hair Growth in Androgenic Alopecia: A 16-Week Double-Blind Randomized Controlled Trial

Choi

Park

Moon³

et al. 2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

We conducted a 16-week double-blind randomized controlled single-center trial to evaluate the safety and efficacy of dermal rice bran supercritical CO 2 extract (RB-SCE) in the treatment of androgenic alopecia. Fifty alopecia patients were randomly assigned to the experimental and placebo groups. The experimental group received a dermal application of 0.5% RB-SCE (8 mL/d) to the head skin for 16 weeks while the control group received a dermal application of placebo. Changes in hair count, diameter, and density were evaluated with a Folliscope ® . Patient satisfaction was evaluated via questionnaire and clinical photographs were rated by dermatologists. The results showed that RB-SCE significantly increased hair density and hair diameter in male subjects. Patient satisfaction and the evaluation of photographs by dermatologists also confirmed the effectiveness of RB-SCE in the treatment of alopecia. No adverse reactions related to RB-SCE were reported. Therefore, RB-SCE shows promise for use in functional cosmetics and pharmaceuticals.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Rice Bran Supercritical CO<sub>2</sub> Extract for Hair Growth in Androgenic Alopecia: A 16-Week Double-Blind Randomized Controlled Trial

Choi

Park

Moon³

et al. 2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated that minoxidil applied twice a day is an effective treatment for AGA, in both men and women [5,49,[77][78][79][80][81].…”

Section: Minoxidilmentioning

confidence: 99%

Androgenetic Alopecia: a Review and Emerging Treatments

Alves¹

2017

CRDOA

View full text Add to dashboard Cite

Androgenetic Alopecia (AGA) is the most common noncicatricial alopecia that leads to the progressive miniaturization of the hair follicle. Scalp terminal hairs are converted into vellus hairs, primarily due to two factors: genetic predisposition and hormonal stimulation.The incidence and prevalence of AGA increases with age. The onset of AGA is gradual, and when this pathology progresses, the anagen phase shortens and the telogen phase remains constant. The shedding area varies from patient to patient and is usually most marked at the vertex in men, while women with AGA generally lose hair diffusely over the crown.Topical minoxidil and oral finasteride (5-alpha-reductase type II inhibitor) are the gold-standard therapies for AGA and are currently the only Food and Drug Administration (FDA)-approved drugs for the treatment of AGA.The currently available treatments for AGA are sometimes perceived as having limited effectiveness; therefore, the identification of new therapies for this pathology is of utmost importance.This article aims to review the pathogenesis, diagnosis of AGA and all the new emerging treatments for this entity in order to prevent its progression and improve the results of this pathology.

show abstract

“…При лечении женской АГА также используется 5% миноксидил. Результаты клинических исследований позволяют предполо-жить, что 5% миноксидил имеет более высокую эф-фективность, чем 2% миноксидил, на основе сред-него изменения не-веллюсных волос [42]. Кроме того, клинические исследования у мужчин показы-вают, что рост волос при использовании 5% минок-сидила имеют примерно 40% пациентов [35].…”

Section: миноксидил не приговор а надеждаunclassified

Minoxidil: a final judgment or a hope?

Gadzhigoroeva¹

2016

Klin. dermatol. venerol.

View full text Add to dashboard Cite

ооо «Институт Красивых волос», Москва, Россия, 105082Миноксидил является базовым препаратом для наружной терапии андрогенетической алопеции у мужчин и женщин. Между тем отношение к миноксидилу неоднозначно как среди пациентов, так и среди врачей. недостаточное понимание этиологии разных форм потери волос, отсутствие ясности в механизмах интеракции миноксидила с клетками-мишенями, в особенности с клетками волосяного фолликула, а также специфичность реакции самих волос на ранних этапах лечения компрометирует действие препарата на волосы и организм человека в целом, ограничивая терапевтические возможности при лечении облысения, снижает комплаентность лечению у пациента. в статье приводится обзор научных исследований о стимулирующих механизмах миноксидила на рост волос, о клинической эффективности и преимуществе использования лекарственной формы препарата в виде пены при андрогенетической алопеции.Ключевые слова: миноксидил, пена миноксидил, андрогенетическая алопеция, лечение. Minoxidil: a final judgment or a hope?A.g. gADzHIgoRoEvA «Institute of nice Hair», Moscow, Russia, 105082Minoxidil is a basic drug for the topical treatment of androgenetic alopecia in males and females. Meanwhile, the attitude of both patients and medical professionals to minoxidil is controversial. Insufficient understanding of the etiology of various forms of hair loss, lack of clear understanding of the mechanisms of interaction between minoxidil and target cells, particularly the hair follicle cells, as well as specific reactions of the hair itself at the early stages of treatment, compromise drug effect on the hair and the entire human body, which results in limited therapeutic potential in treatment of hair loss and reduces patients' compliance. This article provides an overview of the research of stimulatory mechanisms of minoxidil on hair growth, clinical efficacy and benefits of the use of foam-like dosage form of the drug in patients with androgenetic alopecia.

show abstract

A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss

Cited by 241 publications

References 15 publications

Safety and Efficacy of Rice Bran Supercritical CO<sub>2</sub> Extract for Hair Growth in Androgenic Alopecia: A 16-Week Double-Blind Randomized Controlled Trial

Safety and Efficacy of Rice Bran Supercritical CO<sub>2</sub> Extract for Hair Growth in Androgenic Alopecia: A 16-Week Double-Blind Randomized Controlled Trial

Androgenetic Alopecia: a Review and Emerging Treatments

Minoxidil: a final judgment or a hope?

Contact Info

Product

Resources

About